Neoplasms

Nervous System Diseases

All Conditions

Central Nervous System Neoplasms

Nervous System Neoplasms

All Drugs and Chemicals

Cardiotonic Agents

Dihydroxyphenylalanine

Dopamine

Dopamine Agents

Neurotransmitter Agents

Subjects may receive up to two CEST MRI's tests and/or up to two F-DOPA PET. The physician will determine which test is appropriate based on your tumor type, past treatment history and research question. Tests will be completed at initial baseline visit and at least one other MRI/PET after the initial baseline, up to a maximum of four scans.

Imaging using a F-DOPA radioactive tracer to look at the head.

F-DOPA Positron Emission Tomography

A noninvasive diagnostic test for measuring biochemical changes in the brain, especially the presence of tumors.

Chemical Exchange Saturation Transfer Magnetic Resonance Imaging

Terry C Burns, MD, PhD

This research is being done to determine if CEST Magnetic Resonance Imaging and F-dopa PET are feasible techniques to detect metabolic differences between tumor and brain.

A Study of Metabolic Agents Following Brain Radiation

Pilot Imaging Study for CNS Metabolism

Number of subjects in whom glutamate metabolite is detected and measurable via CEST MRI in tumor, brain, and/or the ventricular space.

Number of subjects in whom n-acetylaspartate (NAA) metabolite is detected and measurable via CEST MRI in tumor, brain, and/or the ventricular space.

Total time expressed in minutes required to perform the CEST MRI study and measure metabolites of interest.

Mayo Clinic

Principal Investigator

Skin and Connective Tissue Diseases

Digestive System Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Breast Neoplasms

Melanoma

Head and Neck Neoplasms

Gastrointestinal Neoplasms

Thoracic Neoplasms

Urogenital Neoplasms

Digestive System Neoplasms

Skin Diseases

Breast Diseases

Gastrointestinal Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Male Urogenital Diseases

Patients will receive alisertib orally twice a day for the first 7 days of a 21 day cycle. Patients will also receive pazopanib orally once a day continuously. Treatment continues until disease progression, unacceptable toxicity or patient refusal. The study consists of two components which are the dose finding component and optimally tolerated dose extension with pharmacokinetics component.

Alisertib at the assigned dose by mouth (PO) twice a day for 7 days beginning on day 1 of a 21 day cycle.

Alisertib

Pazopanib at the assigned dose once a day continuously for the duration of treatment.

Pazopanib

Arkadiusz Z. Dudek, M.D.

This phase I trial using the EffTox design will evaluate activity and safety of alisertib, an Aurora A kinase inhibitor, when given in combination with the selective VEGFR inhibitor pazopanib in patients with advanced, previously treated non-hematologic solid tumors.

Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors

STM-01: Phase I EffTox Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy of Solid Tumors

Complete all planned treatment for cycle 1 (defined as 14 doses of alisertib and daily pazopanib) without dose limiting toxicity and are able to start cycle 2 with no more than a 2 week delay.

Adverse events which occur after taking at least one dose of study treatment with either alisertib and/or pazopanib.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Study of Metabolic Agents Following Brain Radiation	NCT06150547	CNS Malignancy	F-DOPA Positron... Chemical Exchan...	18 Years -	Mayo Clinic
Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors	NCT01639911	Malignant Neopl... CNS Malignancy Malignant Neopl... Genitourinary N... Head and Neck N... Melanoma Malignant Neopl...	Alisertib Pazopanib	18 Years -	University of Illinois at Chicago

Spots Global Cancer Trial Database for cns malignancy